Here we assessed whether the combination of two therapeutic monoclonal antibodies, cetuximab, and IMC-A12 that specifically target EGFR and IGF-1R, respectively, would enhance HNSCC tumor response to radiation. The gene discussed is IGF1R; the disease is head and neck squamous cell carcinoma.